Literature DB >> 23465604

Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae carriage at admission in an infant cohort at a tertiary teaching hospital in France.

Laila Rivard-Yazigi1, Jean Ralph Zahar, Sandrine Le Guillou, Christelle Chalouhi, Hervé Lecuyer, Constance Bureau, Xavier Nassif, Dominique Gendrel, Véronique Abadie.   

Abstract

We describe risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae fecal carriage at admission in an infant population. 12.6% were carrying extended-spectrum β-lactamase-producing Enterobacteriaceae. Klebsiella pneumoniae, and Escherichia coli were the most frequently identified species. Prior antibiotic therapy (P = .016; odds ratio, 4.07; 95% confidence interval: 1.29-12.81) and the presence tracheostomy or gastrostomy (P = .018; odds ratio, 3.62; 95% confidence interval: 1.24-10.53) were independently associated with carriage at admission.
Copyright © 2013 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Escherichia coli; Klebsiella pneumoniae; Pediatrics; Rectal screening

Mesh:

Substances:

Year:  2013        PMID: 23465604     DOI: 10.1016/j.ajic.2012.11.016

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  2 in total

1.  Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France.

Authors:  Julie Toubiana; Sandra Timsit; Agnès Ferroni; Marie Grasseau; Xavier Nassif; Olivier Lortholary; Jean-Ralph Zahar; Martin Chalumeau
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

2.  Fecal carriage of multidrug-resistant Escherichia coli by community children in southern Taiwan.

Authors:  I-Fei Huang; Wei-Yang Lee; Jiun-Ling Wang; Chih-Hsin Hung; Hong-Hsiang Hu; Wan-Yu Hung; Yun-Ju Hung; Wen-Chi Chen; Ying-Tso Shen; Ming-Fang Cheng
Journal:  BMC Gastroenterol       Date:  2018-06-15       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.